Clinical Impact of Palliative Treatment Using Octreotide for Inoperable Malignant Bowel Obstruction Caused by Advanced Urological Cancer |
Kubota, Hiroki
(Department of Urology, Kainan Hospital)
Taguchi, Kazumi (Department of Nephro-urology, Nagoya City University Graduate School of Medical Science) Kobayashi, Daichi (Department of Nephro-urology, Nagoya City University Graduate School of Medical Science) Naruyama, Hiromichi (Department of Urology, Kainan Hospital) Hirose, Masahito (Department of Urology, Kainan Hospital) Fukuta, Katsuhiro (Department of Urology, Kainan Hospital) Kubota, Yasue (Department of Nephro-urology, Nagoya City University Graduate School of Medical Science) Yasui, Takahiro (Department of Nephro-urology, Nagoya City University Graduate School of Medical Science) Yamada, Yasuyuki (Department of Urology, Kainan Hospital) Kohri, Kenjiro (Department of Nephro-urology, Nagoya City University Graduate School of Medical Science) |
1 | Bozzetti F, Cozzaglio L, Biganzoli E, et al (2002). Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. Clin Nutr, 21, 281-8. DOI ScienceOn |
2 | Davis MP, Nouneh C (2000). Modern management of cancerrelated intestinal obstruction. Curr Opin Oncol, 2, 343-50. |
3 | Hisanaga T, Shinjo T, Morita T, et al (2010). Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol, 40, 739-45. DOI ScienceOn |
4 | Khoo D, Hall E, Motson R, et al (1994). Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer, 30, 28-30. DOI ScienceOn |
5 | Mercadante S, Ripamonti C, Casuccio A (2000). Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant bowel obstruction. Support Care Cancer, 8, 188-91. DOI |
6 | Mercadante S, Ferrera P, Villari P, Marrazzo A (2004). Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage, 28, 412-16. DOI ScienceOn |
7 | Mercadante S, Casuccio A, Mangione S (2007). Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage, 33, 217-23. DOI ScienceOn |
8 | Mercadante S, Porzio G (2012). Octreotide for malignant bowel obstruction: Twenty years after. Clin Rev Oncol/Hematol, 83, 388-92. DOI ScienceOn |
9 | Mystakidou K, Tsilika E, Kalaidopoulou O, et al (2000). Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, doubleblind, controlled clinical trial. Anticancer Res, 22, 1187-92. |
10 | O'Connor B, Creedon B (2011). Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother, 12, 2205-14. DOI ScienceOn |
11 | Philip J, Depczynski B (1997). The role of total parenteral nutrition for patients with irreversible bowel obstruction secondary to gynecological malignancy. J Pain Symptom Manage, 13, 104-11. DOI ScienceOn |
12 | Ripamonti C, Mercadante S, Groff L, et al (2000). Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage, 19, 23-34. DOI ScienceOn |
13 | Ripamonti C, Mercadante S (2005). Pathophysiology and management of malignant bowel obstruction. In: Doyle D, Hanks GW, McDonald N, Cherny N eds. Oxford textbook of palliative medicine, 3rd edition. Oxford University Press, New York. 496-506. |
14 | Tuca A, Guell E, Martinez-Losada E, et al (2012). Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Management Res, 4, 159-69. |
15 | WHO Handbook for Reporting Results of Cancer Treatment (1979). WHO, Geneva, 1979. |